CGEM
Cullinan Therapeutics Inc
NASDAQ · Biotechnology
$12.23
+0.38 (+3.21%)
Open$12.09
Previous Close$11.85
Day High$12.53
Day Low$11.86
52W High$13.43
52W Low$5.68
Volume—
Avg Volume667.8K
Market Cap722.50M
P/E Ratio—
EPS$-3.68
SectorBiotechnology
Analyst Ratings
Strong Buy
17 analysts
Price Target
+75.4% upside
Current
$12.23
$12.23
Target
$21.45
$21.45
$16.94
$21.45 avg
$32.37
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 156.49M | 140.29M | 129.25M |
| Net Income | -25,188,754 | -25,282,384 | -20,083,076 |
| Profit Margin | -16.1% | -18.0% | -15.5% |
| EBITDA | -32,256,643 | -27,830,603 | -25,262,091 |
| Free Cash Flow | -9,992,952 | -10,952,071 | -13,180,515 |
| Rev Growth | +6.1% | +12.8% | -3.3% |
| Debt/Equity | 0.08 | 0.08 | 0.10 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $223.43 | +2.01% | 165.4 | 394.89B |
| AMGN | Amgen Inc | $384.32 | +4.49% | 26.8 | 206.95B |
| GILD | Gilead Sciences Inc | $152.50 | +2.10% | 23.3 | 189.20B |
| VRTX | Vertex Pharmaceuticals Inc | $477.92 | +4.17% | 33.7 | 123.82B |
| REGN | Regeneron Pharmaceuticals | $785.51 | +2.46% | 18.4 | 83.03B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.16 | -0.93% | 995.2 | 43.35B |